Share on LinkedInShare on LinkedIn

ARTICLE · 08 AUGUST 2013

Lessons Learned From The Glaxosmithkline Bribery Investigation

Sheppard
Sheppard
Contributor
Sheppard

Sheppard

Businesses turn to Sheppard to deliver sophisticated counsel to help clients move ahead. With more...

View firm profile
Explore more from Sheppard

The recent enforcement of Chinese anti-bribery laws against British pharmaceutical company GlaxoSmithKline highlights the compliance challenges faced by foreign companies operating in China.

United StatesInternational Law

The recent enforcement of Chinese anti-bribery laws against British pharmaceutical company GlaxoSmithKline (GSK) highlights the compliance challenges faced by foreign companies operating in China.

GSK's Chinese subsidiary is accused of funneling almost $500 million in bribes to doctors and hospitals in China in exchange for purchasing or prescribing the company's products.  The alleged bribes included sexual favors, cash, and invitations to join high-end academic conferences.  GSK employees also allegedly accepted kickbacks and improper commission fees, issued fake invoices, and wrote special bills related to the value-added tax.

According to the Chinese public security ministry, the goal of the alleged scheme was "to raise drug prices, expand sales, and reap inappropriate profits."  One GSK executive told Chinese state television the bribes increased the prices Chinese patients paid for GSK drugs by as much as 30 percent.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from